Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas
and mostly affecting young patients. A second peak is seen in patients above 60 years of …

Background Incorporating brentuximab vedotin into the treatment of advanced-stage classic
Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However …

Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1
protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL) …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Importance To our knowledge, this is the first clinical trial designed to investigate concurrent
treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or …

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma
remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus …

Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting
programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed …

Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom
autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent …